Vaccitech, a clinical-stage biopharmaceutical company, has raised $168 million in Series B funding. The investors included Future Planet Capital, M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and Oxford Sciences Innovation.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: